这项工作得到了NIH拨款DK32083，JDRF拨款2-SRA-2015-51-Q-R和2-SRA-2018-533-S-B的支持。

该研究方案得到了科罗拉多州多个机构审查委员会的批准。
1. 缓冲液制备
<ol><li>制作标记缓冲液（2x PBS，pH 7.9）。使用 400 mL 蒸馏去离子 （DD） 水，加入 100 mL 的 10x PBS。要调节溶液的pH值，请加入NaOH直至达到7.9。</li>
	<li>通过将 1 mg 生物素溶解到先前创建的 588 μL 标记缓冲液中，创建 3 mM 生物素。通过将 150 nmol的 Ru 磺基-NHS 溶解到 50 μL 标记缓冲液中，制成 3 mM Ru 磺基-NHS。</li>
	<li>通过取 500 mL 的 1x PBS 并向溶液中加入 5 g 牛血清白蛋白 （BSA） 来制作抗原缓冲液 （1% BSA）。准备0.5M乙酸溶液。使用Trizma碱制备1M Tris-HCl缓冲液，并将pH调节至9.0。</li>
	<li>对于包衣缓冲液（3%阻断剂A），取500 mL 1x PBS并加入15 g阻断剂A.通过将5000 mL 1x PBS与2.5 mL吐温20混合来制备洗涤缓冲液（0.05%吐温20，PBST）。通过加入 500 mL DD 水和 500 mL 含有表面活性剂的 4x 读取缓冲液 T 来创建读数缓冲液（含表面活性剂的 2x 读取缓冲液 T）。 注意:为了保持测定之间的一致性，重要的是生物素和Ru Sulfo-NHS溶液都是在标记程序之前创建的，而不是创建和存储以备将来使用。</li>
</ol>2. 分别用生物素和Ru磺基-NHS标记每种抗原蛋白
注意:要获得更有效的标记反应，请使用≥0.5mg / mL的抗原蛋白浓度。
<ol><li>计算每种抗原蛋白的摩尔数以及生物素和Ru磺基-NHS的摩尔数。在抗原蛋白中加入适量的生物素或Ru磺基-NHS抗原蛋白，按抗原蛋白与生物素或如磺基-NHS的摩尔比进行标记反应。<ol><li>对于分子量较小（≤10 kDa）的抗原，例如胰岛素原蛋白，请使用1:5的摩尔比（抗原:生物素和Ru磺基-NHS）。对于分子量较大（>50 kDa）的抗原，例如GAD蛋白，使用1:20的摩尔比。对于具有中等分子量（10-50 kDa）的抗原，请使用在1:5-1:20之间调整的摩尔比。</li>
	</ol></li>
	<li>对于生物素和Ru Sulfo-NHS，将每个抗原重量除以其相应的分子量，以获得每个抗原摩尔数。将摩尔数除以浓度以获得生物素的体积。对Ru Sulfo-NHS重复此操作。</li>
	<li>使用适当的摩尔比将抗原蛋白与生物素混合，在步骤2.2中测定。然后对Ru Sulfo-NHS做同样的事情。 注意:为了提高标记反应的效率，缓冲液系统中的任何还原性化学物质（如Tris或甘氨酸）都需要通过施胶离心柱交换到pH 7.9的2x PBS缓冲液中。生物素和Ru Sulfo-NHS的标记协议是相同的。</li>
	<li>用铝箔覆盖反应管，并在室温（RT）下孵育1小时。用箔纸覆盖反应管的原因是生物素和Ru磺基-NHS试剂都对光敏感。</li>
	<li>在反应管孵育时灌注2 mL或5 mL离心柱（离心柱的大小由上传到色谱柱上的体积决定）。用2x PBS缓冲液填充离心柱，然后每次以1，000 x g 离心2分钟，共三次。</li>
	<li>反应管完成孵育后停止标记反应。要停止反应，通过将标记的抗原蛋白通过离心柱一次来纯化标记的抗原蛋白。然后将色谱柱以1，000 x g 离心2分钟。</li>
	<li>通过将存在的抗原蛋白的量除以最终体积来计算总标记抗原浓度。每管等分50μL纯化的标记抗原蛋白，并将等分试样储存在-80°C以备长期使用。 注意:重要的是要注意，每次离心柱通过抗原蛋白时，都会有大约90-95%的保留率。</li>
</ol>3.确定测定（棋盘测定）中两种标记抗原的最佳浓度和比例
注意:由于该7-Plex测定中的ECL-IAA测定需要对血清样品进行酸处理，因此每种抗原的棋盘测定在与标记的抗原混合物孵育之前必须经过此步骤。
<ol><li>在运行多重测定之前，分别对每种抗原应用棋盘测定。步骤 3.2-3.6 将使用 GAD65 作为示例。</li>
	<li>计算标记的GAD65蛋白的稀释度。生物素化GAD65的第一个混合物溶液的推荐目标浓度为2000 ng / mL，Ru磺基-NHS标记的GAD65为1000 ng / mL。如果储备溶液中生物素化和Ru磺基-NHS标记的GAD65的浓度均为1.0μg/ μL，则560μL工作溶液中生物素化GAD65所需的体积将为1.12μL，700μL工作溶液中标记的GAD65的Ru磺基-NHS所需的体积将为0.7μL。</li>
	<li>将 1.12 μL 生物素化 GAD65 蛋白与 240 μL 链霉亲和素偶联接头 1 混合在一个试管中和 160 μL 1% BSA 中。将混合物在室温下孵育30分钟。向管中加入 160 μL 终止溶液，并将混合物在室温下再孵育 30 分钟。</li>
	<li>进行连续稀释。将 280 μL 混合物放入新管中，加入 280 μL 终止液以 1:2 稀释。准备几个新管。重复此步骤以运行生物素标记的GAD65抗原的水平连续稀释（参考先前的出版物12）。</li>
	<li>将 0.7 μL Ru 磺基-NHS 标记的 GAD65 （1 μg/μL） 蛋白与 700 μL 终止溶液混合。然后将 350 μL 混合物放入新试管中，加入 350 μL 终止液以 1:2 稀释。准备几个新管，重复此步骤以对Ru磺基-NHS标记的GAD65抗原进行垂直连续稀释。</li>
	<li>制备两个血清样品，一个样品对 GADA 高度阳性，一个样品对 GADA 呈阴性，每个样品的体积为 0.75 mL。将 15 μL 阳性血清等分到 96 孔 PCR 板左半部分的每个孔中。将 15 μL 阴性血清等分到 96 孔 PCR 板右半部分的每个孔中。</li>
	<li>向每个孔中加入 18 μL 0.5 M 乙酸并混合。在室温下孵育45分钟。 准备一个新的96孔PCR板。根据系列稀释液，向每个孔中加入 17.5 μL 生物素标记的抗原和 17.5 μL 的 Ru Sulfo-NHS 标记的抗原（参见之前的出版物12）。</li>
	<li>继续步骤5.2至9.1中描述的其余测定步骤。</li>
	<li>确定高正样本的信号与相应的负样本信号的比值。通过确定正负信号比例最高或接近最高比率的点，选择生物素标记抗原和Ru Sulfo-NHS标记抗原的最佳浓度。在此比率计算中，请考虑从负样本获得的低背景信号。 注意:来自棋盘测定的Ru Sulfo-NHS和生物素标记抗原蛋白的最佳浓度如下所示:GAD65为30 ng / mL和200 ng / mL，胰岛素原为120 ng / mL和120 ng / mL，IA-2为10 ng / mL和42 ng / mL，TG为80 ng / mL和80 ng / mL，TPO为8 ng / mL和16 ng / mL， ThG 为 31 ng/mL 和 31 ng/mL，IFNα 为 12 ng/mL 和 12 ng/mL。</li>
</ol>4. 创建混合接头偶联抗原溶液
<ol><li>根据棋盘测定选择每种抗原的最佳浓度。将生物素和Ru磺基-NHS标记的抗原稀释至合理的工作浓度。</li>
	<li>将不同的接头与每种独特的生物素化抗原蛋白结合。对于一个 96 孔板测定，将 4 μL 生物素化的 GAD65、TPO、tTG、ThG、胰岛素原、IFN-α 和 IA-2 蛋白与 240 μL 链霉亲和素偶联接头 1、2、3、4、8、9 和 10 混合到单独的管中（图 1）。然后每管加入 156 μL PBS/1% BSA。将混合物在室温下孵育30分钟。</li>
	<li>向每个试管中加入 160 μL 终止溶液，并在室温下再孵育 30 分钟。从每个试管中取出 400 μL 接头偶联抗原，并将所有 7 种抗原组合在一起。加入 1.2 mL 终止液，然后将 4 μL 标记的 GAD65、TPO、tTG、ThG、胰岛素原、IFN-α 和 IA-2 抗原加入混合物中。现在抗原溶液已准备好用于测定。</li>
</ol>5. 用标记的抗原孵育血清样品
注意:由于此 7-Plex 测定中的 ECL-IAA 测定需要对血清样品进行酸处理，因此每种血清都需要在与标记的抗原混合物孵育以进行此 7-Plex 测定之前进行酸处理步骤。
<ol><li>将每孔 15 μL 血清分装用于 96 孔 PCR 板。向每个孔中加入 18 μL 0.5 M 乙酸并混合。在室温下孵育45分钟。 准备一个新的 96 孔 PCR 板并将 35 μL 抗原溶液等分到每个孔中。</li>
	<li>当板仍在孵育时，向抗原板中的每个孔中加入 13 μL 1 M Tris pH 9.0 缓冲液。在每个孔的侧面添加缓冲液以限制Tris缓冲液和抗原的混合。孵育完成后，取 25 μL 酸处理的血清，并立即将其移液到抗原板上的每个孔中。搅拌溶液并用PCR密封箔覆盖板以避免光照。</li>
	<li>在室温下，将板放在摇床上，以低速设置，1小时。之后，将板储存在4°C，让板孵育18-24小时。</li>
</ol>6. 准备多重板
<ol><li>从4°C冰箱中取出一个多重板，让板进入室温。多重板处于室温状态后，向每个孔中加入 150 μL 3% 阻断剂 A。用密封箔覆盖多重板。将板在4°C冰箱中孵育过夜。 注意:检测第 1 天包括步骤 4 至 6。</li>
</ol>7. 将血清/抗原转入多重平板
<ol><li>第二天，将纸巾放在桌子上，然后从冰箱中取出孵育多重板。清空板中的所有缓冲液。为此，将板倒置并将其拍在准备好的纸巾上，直到任何孔中都没有缓冲液。</li>
	<li>通过向每个孔中加入 150 μL PBST 来清洗多重板。如步骤 7.1 中所述，丢弃缓冲区，并重复此步骤三次。将 30 μL 血清/抗原孵育到多重板的每个孔中。用箔纸覆盖板以限制其暴露在光线下。将板放在设置为低速的摇板器上，在室温下放置1小时。</li>
</ol>8.清洗板并加入读取缓冲液
<ol><li>通过将平板倒置并甩出溶液，从多重平板中取出血清/抗原孵育物。向所有孔中加入 150 μL PBST，并通过再次将板倒置并轻弹溶液从板中取出缓冲液。重复此步骤三次。第三次洗涤完成后，向每个孔中加入 150 μL 读数缓冲液。 注意:气泡会干扰酶标仪机器准确分析印版结果的能力，应不惜一切代价避免。</li>
</ol>9. 读取板并分析数据
<ol><li>在读板器上对准备好的板进行计数，以每秒计数（CPS）为单位读取所有值。</li>
	<li>使用从酶标仪机获得的抗体水平计算测定的相对指数，公式如下: 指数值 = [CPS（样本）- CPS（负标准）] / [CPS（正标准）- CPS（负标准）]。</li>
	<li>使用已确定的临界值确定哪些抗体结果为阴性或阳性。 注意:检测第 2 天包括步骤 7 至 9。</li>
</ol>

<ol>
	<li>Harjutsalo, V., Sjoberg, L., Tuomilehto, J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Time+trends+in+the+incidence+of+type+1+diabetes+in+Finnish+children:+a+cohort+study.">Time trends in the incidence of type 1 diabetes in Finnish children: a cohort study.</a> Lancet. 371 (9626), 1777-1782 (2008).</li><li>Vehik, K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Increasing+incidence+of+type+1+diabetes+in+0-+to+17-year-old+Colorado+youth.">Increasing incidence of type 1 diabetes in 0- to 17-year-old Colorado youth.</a> Diabetes Care. 30 (3), 503-509 (2007).</li><li>Atkinson, M. A., Eisenbarth, G. S., Michels, A. W. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Type+1+diabetes.">Type 1 diabetes.</a> Lancet. 383 (9911), 69-82 (2014).</li><li>Insel, R. A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Staging+presymptomatic+type+1+diabetes:+a+scientific+statement+of+JDRF,+the+Endocrine+Society,+and+the+American+Diabetes+Association.">Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association.</a> Diabetes Care. 38 (10), 1964-1974 (2015).</li><li>Barker, J. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Autoantibody+"subspecificity"+in+type+1+diabetes:+risk+for+organ-specific+autoimmunity+clusters+in+distinct+groups.">Autoantibody "subspecificity" in type 1 diabetes: risk for organ-specific autoimmunity clusters in distinct groups.</a> Diabetes Care. 28 (4), 850-855 (2005).</li><li>Triolo, T. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Additional+Autoimmune+Disease+Found+in+33%+of+Patients+at+Type+1+Diabetes+Onset.">Additional Autoimmune Disease Found in 33% of Patients at Type 1 Diabetes Onset.</a> Diabetes Care. 34 (5), 1211-1213 (2011).</li><li>de Graaff, L. C., Smit, J. W., Radder, J. K. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Prevalence+and+clinical+significance+of+organ-specific+autoantibodies+in+type+1+diabetes+mellitus.">Prevalence and clinical significance of organ-specific autoantibodies in type 1 diabetes mellitus.</a> Netherlands Journal of Medicine. 65 (7), 235-247 (2007).</li><li>Yu, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Proinsulin/Insulin+autoantibodies+measured+with+electrochemiluminescent+assay+are+the+earliest+indicator+of+prediabetic+islet+autoimmunity.">Proinsulin/Insulin autoantibodies measured with electrochemiluminescent assay are the earliest indicator of prediabetic islet autoimmunity.</a> Diabetes Care. 36 (8), 2266-2270 (2013).</li><li>Yu, L., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Distinguishing+persistent+insulin+autoantibodies+with+differential+risk:+nonradioactive+bivalent+proinsulin/insulin+autoantibody+assay.">Distinguishing persistent insulin autoantibodies with differential risk: nonradioactive bivalent proinsulin/insulin autoantibody assay.</a> Diabetes. 61 (1), 179-186 (2012).</li><li>Miao, D., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=GAD65+autoantibodies+detected+by+electrochemiluminescence+assay+identify+high+risk+for+type+1+diabetes.">GAD65 autoantibodies detected by electrochemiluminescence assay identify high risk for type 1 diabetes.</a> Diabetes. 62 (12), 4174-4178 (2013).</li><li>Gu, Y., Zhao, Z., High, H., Yang, T., Yu, L. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Islet+Autoantibody+Detection+by+Electrochemiluminescence+(ECL)+Assay.">Islet Autoantibody Detection by Electrochemiluminescence (ECL) Assay.</a> Journal of Clinical &amp; Cellular Immunology. 8 (6), (2017).</li><li>Gu, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Electrochemiluminescence+Assays+for+Human+Islet+Autoantibodies.">Electrochemiluminescence Assays for Human Islet Autoantibodies.</a> Journal of Visualized Experiments. (133), e57227 (2018).</li><li>Gu, Y., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=High-throughput+multiplexed+autoantibody+detection+to+screen+type+1+diabetes+and+multiple+autoimmune+diseases+simultaneously.">High-throughput multiplexed autoantibody detection to screen type 1 diabetes and multiple autoimmune diseases simultaneously.</a> Ebiomedicine. 47, 365-372 (2019).</li><li>Dongmei, M., A, K. S., Li Zh, K., Michelle, G., Ling, J., Taylor, A. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Electrochemiluminescence+Assays+for+Insulin+and+Glutamic+Acid+Decarboxylase+Autoantibodies+Improve+Prediction+of+Type+1+Diabetes+Risk.">Electrochemiluminescence Assays for Insulin and Glutamic Acid Decarboxylase Autoantibodies Improve Prediction of Type 1 Diabetes Risk.</a> Diabetes Technology &amp; Therapeutics. 17 (2), 119-127 (2015).</li><li>Steck, A. K., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=ECL-IAA+and+ECL-GADA+Can+Identify+High-Risk+Single+Autoantibody-Positive+Relatives+in+the+TrialNet+Pathway+to+Prevention+Study.">ECL-IAA and ECL-GADA Can Identify High-Risk Single Autoantibody-Positive Relatives in the TrialNet Pathway to Prevention Study.</a> Diabetes Technology &amp; Therapeutics. 18 (7), 410-414 (2016).</li><li>Fouts, A., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Do+Electrochemiluminescence+Assays+Improve+Prediction+of+Time+to+Type+1+Diabetes+in+Autoantibody-Positive+TrialNet+Subjects.">Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects.</a> Diabetes Care. 39 (10), 1738-1744 (2016).</li><li>Sosenko, J. M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=The+Use+of+Electrochemiluminescence+Assays+to+Predict+Autoantibody+and+Glycemic+Progression+Toward+Type+1+Diabetes+in+Individuals+with+Single+Autoantibodies.">The Use of Electrochemiluminescence Assays to Predict Autoantibody and Glycemic Progression Toward Type 1 Diabetes in Individuals with Single Autoantibodies.</a> Diabetes Technology &amp; Therapeutics. 19 (3), 183-187 (2017).</li><li>Zhao, Z., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Higher+Sensitivity+and+Earlier+Identification+of+Celiac+Disease+Autoimmunity+by+a+Nonradioactive+Assay+for+Transglutaminase+Autoantibodies.">Higher Sensitivity and Earlier Identification of Celiac Disease Autoimmunity by a Nonradioactive Assay for Transglutaminase Autoantibodies.</a> Journal of Immunology Research. 2016, 5 (2016).</li><li>Zhang, B., Kumar, R. B., Dai, H., Feldman, B. J. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+plasmonic+chip+for+biomarker+discovery+and+diagnosis+of+type+1+diabetes.">A plasmonic chip for biomarker discovery and diagnosis of type 1 diabetes.</a> Nature Medicine. 20 (8), 948-953 (2014).</li><li>Tsai, C. T., Robinson, P. V., Spencer, C. A., Bertozzi, C. R. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Ultrasensitive+Antibody+Detection+by+Agglutination-PCR+(ADAP).">Ultrasensitive Antibody Detection by Agglutination-PCR (ADAP).</a> American Chemical Society Central Science. 2 (3), 139-147 (2016).</li><li>Yim, S. W., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Four-color+alternating-laser+excitation+single-molecule+fluorescence+spectroscopy+for+next-generation+biodetection+assays.">Four-color alternating-laser excitation single-molecule fluorescence spectroscopy for next-generation biodetection assays.</a> Clinical chemistry. 58 (4), 707-716 (2012).</li><li>Bale, S. S., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+highly+sensitive+microsphere-based+assay+for+early+detection+of+Type+I+diabetes.">A highly sensitive microsphere-based assay for early detection of Type I diabetes.</a> Technology. 02 (03), 200-205 (2014).</li><li>Ziegler, A. G., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=3+Screen+ELISA+for+High-Throughput+Detection+of+Beta+Cell+Autoantibodies+in+Capillary+Blood.">3 Screen ELISA for High-Throughput Detection of Beta Cell Autoantibodies in Capillary Blood.</a> Diabetes Technology &amp; Therapeutics. 18 (11), 687-693 (2016).</li><li>Schlosser, M., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=Diabetes+Antibody+Standardization+Program:+evaluation+of+assays+for+insulin+autoantibodies.">Diabetes Antibody Standardization Program: evaluation of assays for insulin autoantibodies.</a> Diabetologia. 53 (12), 2611-2620 (2010).</li><li>Zhao, Z., et al. <a target="_blank" href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed&cmd=Search&doptcmdl=Citation&defaultField=Title+Word&term=A+multiplex+assay+combining+insulin,+GAD,+IA-2+and+transglutaminase+autoantibodies+to+facilitate+screening+for+pre-type+1+diabetes+and+celiac+disease.">A multiplex assay combining insulin, GAD, IA-2 and transglutaminase autoantibodies to facilitate screening for pre-type 1 diabetes and celiac disease.</a> Journal of Immunological Methods. 430, 28-32 (2016).</li></ol>

作者没有什么可透露的。

在众多针对 1 型糖尿病的国家和国际临床试验中，单一 ECL 测定检测胰岛自身抗体和乳糜泻谷氨酰胺转移酶 （TGA） 自身抗体的性能已得到证实8，9，10，11。在这些试验中，当根据现有的"金"标准RBA进行评估时，该测定提高了自身抗原检测的灵敏度和特异性。在单次ECL测定和RBA14，15，16，17之间区分高亲和力和高风险胰岛自身抗体与低风险，低亲和力信号时，可以看到增强的疾病特异性。在单一ECL检测的基础上，我们提出了一种新的高通量多重ECL自身抗体检测，使我们能够同时筛查T1D以及几种适用的自身免疫性疾病。
多重ECL检测使用多重板，可将多达10种自身抗体检测组合到一个孔中。在本研究中，将7种自身抗体测定组合在一起。自身抗体包括 3 种 IAb（IAA、GADA 和 IA-2A）、2 种自身免疫性甲状腺疾病自身抗体（TPOA 和 ThGA）、乳糜泻自身抗体 （TGA） 和 APS-1 干扰素 α 自身抗体 （IFNαA）。通常，该测定机制基于先前发表的9，10，12，18的单一ECL测定，并进行了一些修改。多重ECL检测与单一ECL检测的主要区别在于，在液相中形成的每个抗体-抗原复合物都被限制在特定的接头上（图1）。生物素标记的抗原与链霉亲和素偶联物一起孵育，链霉亲和素是用于形成特异性抗原-接头复合物的接头。抗体-抗原免疫复合物在与患者血清孵育后形成，并通过多重板每个孔上的特异性接头系统捕获到特定点上。Ru Sulfo-NHS标记的抗原被抗体捕获，同时提供电化学发光信号。酶标仪可以检测来自每个孔中的点光源的多达 10 个不同信号。为了在进行长期研究时保持板之间的自身抗体测定一致，我们建议使用相同的接头。
在建立多重ECL检测之前，需要分别在多重板上优化每种自身抗体的单次ECL检测，并在常规ECL板上针对RBA和单ECL检测进行验证。为了增强棋盘格测定，对多重板上的相关自身抗体测定，使用了高阳性患者和阴性患者样本。进行棋盘测定后，计算7种自身抗体测定中每种最理想的Ru Sulfo-NHS和生物素标记抗原浓度。下面显示了这些浓度:GAD65为30 ng/mL和200 ng/mL，胰岛素原为120 ng/mL和120 ng/mL，IA-2为10 ng/mL和42 ng/mL，TG为80 ng/mL和80 ng/mL，TPO为8 ng/mL和16 ng/mL，ThG为31 ng/mL和31 ng/mL， IFNα 13 分别为 12 ng/mL 和 12 ng/mL。将所有测定组合在一起后，可能需要根据实际多重测定的结果进一步调整棋盘测定中某些抗原的浓度。
由于IAA包含在目前的多重ECL测定中，因此在将血清与抗原孵育之前，必须对血清样品进行酸处理，如先前的研究12所述。通常，当在多重检测中加入额外的自身抗体时，检测背景会受到影响，并且来自孔中一个点的极高信号可能会通过串扰阻碍附近斑点的结果。因此，对于最高阳性样品，每个自身抗体的最大CPS需要限制为20，000个计数，或更低。据我们所知，为了减少涉及的串扰量，在设计斑点图时，应将背景较低的自身抗体与计数频率较高的斑点分开。
在每次测定中内部使用高阳性和阴性对照，以计算被测未知样品的准确指数。为了准确评估和监测测定的灵敏度，使用了设置在测定上限附近的低阳性对照。这些标准阳性和阴性对照以批量和等分试样形式创建以供长期使用，并储存在-20°C或更低温度下，以确保测定之间的一致性。出于质量保证的目的，每次检测中都运行两次样品，然后重新运行每个阳性结果，并在第二天通过新的ECL检测来确认样品。如果对第一和第二验证性测定有任何分歧，则需要进行第三次测定。在进行的三种测定中，一致的两种测定的结果（例如，+，+或-,-）决定了样品的最终结果（阳性或阴性）。
在过去十年中，许多研究小组正在寻求一种利用多重方法将多种自身抗体检测组合成一个孔以筛选大量人群的高通量检测。有一些研究正在使用不同类型的技术进行多重自身抗体检测19，20，21，22，但在研究T1D时，这些检测的灵敏度和特异性与当前的"黄金"标准RBA没有可比性。所使用的这些不同类型的平台未通过国际胰岛自身抗体标准化计划（IASP）研讨会或通过在临床试验中测试大型队列进行验证。在德国最近进行的基于一般人群的筛查中，Kronus 分发的高通量联合检测 3 Screen ICATM ELISA 正被用作一线筛查的工具，以检测三种 IAb、GADA、IA-2A 和 ZnT8A，以实现儿童 T1D23 的早期诊断。3 筛选 ELISA 测定法可在 3 个分离的孔中测量 3 种自身抗体，消耗大量血清，或在混合所有 3 种检测的单个孔中测量 3 种自身抗体。如果 3 屏幕 ELISA 测定中的一个孔呈阳性，则无法区分存在三种自身抗体中的哪一个。该测定的最大缺点是无法包括IAA测量。正如IASP讲习班所证明的那样，ELISA进行的所有IAA结果都不具有可接受的敏感性和特异性24。IAA通常是第一个出现的IAb，在幼儿中患病率很高。与IAA一起进行IAb筛查对儿童是必要的，在没有IAA评估社区T1D风险的情况下进行这种筛查是不可接受的。此外，没有已发表的研究或数据显示 Kronus IAb 试剂盒检测更具 T1D 疾病特异性，能够区分高风险和低风险 IAb。在本研究中，7-Plex ECL测定使用大量新诊断的T1D13患者进行了验证。与当前标准RBA和成熟的单一ECL检测相比，7-Plex检测能够以相同的检测特异性保持100%的阳性性（表4）。目前，与标准RBA并行的4-Plex ECL测定正在应用于正在进行的大型临床试验:儿童自身免疫筛查（ASK）研究。该试验对丹佛大都会区普通人群中的儿童进行T1D和乳糜泻筛查。与ASK研究中使用的标准RBA相比，多重ECL测定显示出出色的灵敏度和更高的疾病特异性，与我们之前使用单个ECL研究的报告相同25。此外，与相应的 4 次 ECL 和 RBA 单次检测相比，我们的 4-Plex ECL 检测表明，劳动力、成本和血清量显著减少了 70%。使用多重ECL测定，我们可以用不同的数字定制每个孔，代表不同的自身抗体（最多10种），以测试特定于特定临床位置需求的不同自身免疫性疾病。
本研究显示，对于使用多重板的多重ECL测定，观察到一些局限性。与抗原一起孵育的血清的最终稀释度无法调整，以产生组合在单个孔中的每个自身抗体测定的最佳条件。观察到来自T1D患者的9个样本（9/1026）对特定自身抗体有假阴性结果。在7-Plex ECL测定中，7个假阴性是TPOA，2个是ThGA，但在单一ECL测定和RBA中都表现出高阳性结果（图2 和 3）。在所有9个样品进一步稀释后，它们在多重板上呈阳性。这个结果是由我们所说的"prozone"现象引起的。这种现象导致样品显示假阴性结果，因为高抗体滴度会影响抗原抗体晶格的形成。在设置多重检测时，对于每种联合自身抗体，建议对具有非常高滴度的样品进行预测试，以确定用于抗原孵育的血清的可选稀释度。或者，应选择具有类似优化条件的自身抗体检测以形成组合检测，从中对每种自身抗体获得最佳检测灵敏度和特异性。在本研究中，来自健康正常对照的7个样品（7/1022）在7-Plex测定中导致多种自身抗体的假阳性，但是在运行单个ECL测定和RBA（图2 和 3）后，发现这些自身抗体在两种测定中均为阴性。对于这些小样本子集，多重平板上发生这些假阳性结果的原因目前尚不清楚。对于多重ECL检测的当前应用，所有阳性样品都重复其相应的单一ECL检测以确认阳性，从而消除了多重ECL检测中的假阳性误差。

1型糖尿病（T1D）是一种严重的慢性疾病，最常见于儿童期。目前，美国约有 140 万人患有 T1D;引人注目的是，全球T1D的发病率以每年3-5%的速度稳步增长，并且在过去二十年中翻了一番，特别是在幼儿中1，2。血液循环中的胰岛自身抗体（IAbs）是目前最可靠的生物标志物。IAbs可能在临床T1D发展前数年出现3。目前，四种主要的IAb广泛用于T1D诊断和风险筛查，包括胰岛素自身抗体（IAA），谷氨酸脱羧酶-65（GADA），胰岛素瘤抗原-2（IA-2A）和锌转运蛋白-8（ZnT8A）。这四个IAb在预测T1D发展方面同样重要。T1D 的分类最近被重新定义为存在任何 4 个 IAb 中的 ≥2 个，血糖代谢正常，作为疾病 14 期。
在年轻人的糖尿病自身免疫研究（DAISY）中，发现四分之一有T1D风险的儿童可能会进展为胰岛，乳糜泻，甲状腺或类风湿自身免疫，更引人注目的是，大约40%被诊断患有T1D的患者最终会发展为额外的自身免疫性疾病5，6，7.自身抗体的鉴定对于预测和诊断这些自身免疫性疾病至关重要，应为患者提供更好的临床护理。目前还没有简单且廉价的方法来筛查这些多种自身免疫性疾病。目前使用标准放射性结合测定（RBA）和单一自身抗体测量的筛选方法对于大规模筛选来说既费力又低效。
在这里，我们将描述新开发的简单多重ECL检测，我们已经使用单个ECL检测平台8，9，10，11对其进行了验证。多重 ECL 检测将 7 种自身抗体检测结合到一个孔中，仅使用 15 μL 血清，能够同时筛查 T1D 和多种相关自身免疫性疾病，包括乳糜泻、自身免疫性甲状腺疾病和 APS-1。当时尚未开发ZnT8A ECL测定，因此未包含在多重测定中。多重ECL检测为一般人群筛查T1D和多种自身免疫性疾病提供了出色的工具。

<table>
	<tbody>
		<tr>
			<td>4 &#176;C refrigerator</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>&#8211;80 &#176;C and -20 &#176;C freezers</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>96-well Plate Shaker</td>
			<td>Wallac - Delfi</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>96-well round bottom plate</td>
			<td>Fisher</td>
			<td>8408220</td>
			<td></td>
		</tr>
		<tr>
			<td>Acetic acid solution</td>
			<td>Fisher</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Aluminum foil</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Antigen proteins</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Human GAD65 full length protein</td>
			<td>Diamyd</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Human ThG full length protein</td>
			<td>BioMart</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Human TPO full length protein</td>
			<td>BioMart</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>IA-2 intracellular domain protein</td>
			<td>BioMart</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>IFN-&#945; protein</td>
			<td>Abcam</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Proinsulin protein</td>
			<td>AmideBio</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>tTG protein</td>
			<td>DiaRect</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Biotin</td>
			<td>Sigma</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Bottle-Top 500 mL , Filter Units</td>
			<td>Fisher</td>
			<td>0974064A or B</td>
			<td></td>
		</tr>
		<tr>
			<td>Bovine Serum Albumin</td>
			<td>Sigma</td>
			<td>A-7906</td>
			<td></td>
		</tr>
		<tr>
			<td>Distilled deionized (DD) water</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>HCl</td>
			<td>Fisher</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Ice maker</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Ice trays</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>MSD Sector</td>
			<td>Perkin-Elmer</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Multi-channel pipette</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>NaOH</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Paper tower</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>PBS</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>pH meter</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Pipette-Aid</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Pipettes/tips</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Ru Sulfo-NHS</td>
			<td>MSD (R91AN)</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Trizma Base</td>
			<td>Fisher</td>
			<td>BP152-5</td>
			<td></td>
		</tr>
		<tr>
			<td>Tween 20</td>
			<td>Sigma</td>
			<td>P-1379</td>
			<td></td>
		</tr>
		<tr>
			<td>Uplex Development Kit</td>
			<td>MSD</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>96-well UPlex plate</td>
			<td>MSD</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Blocker A</td>
			<td>MSD</td>
			<td>R93AA</td>
			<td></td>
		</tr>
		<tr>
			<td>Linker-Streptavidin</td>
			<td>MSD</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Read buffer</td>
			<td>MSD</td>
			<td>R92TC</td>
			<td></td>
		</tr>
		<tr>
			<td>Stop Solution</td>
			<td>MSD</td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>Vortex mixer</td>
			<td></td>
			<td></td>
			<td></td>
		</tr>
		<tr>
			<td>ZeBa Column</td>
			<td>Pierce</td>
			<td>89892</td>
			<td></td>
		</tr>
	</tbody>
</table>

a high-throughput electrochemiluminescence 7-plex assay simultaneously screening for type 1 diabetes and multiple autoimmune diseases

胰岛自身抗体（IAbs）广泛用于1型糖尿病（T1D）的诊断和预测。胰岛素 （IAA）、谷氨酸脱羧酶-65 （GADA）、胰岛素瘤抗原-2 （IA-2A） 和锌转运蛋白-8 （ZnT8A） 的四种主要 IAb 在疾病预测中同样重要。目前，高达40%的T1D诊断患者继续发展为其他自身免疫性疾病。不幸的是，目前使用单一自身抗体进行测量的筛选方法对于大规模筛选研究来说既费力又低效。我们最近开发了一种简单的多重电化学发光（ECL）测定来解决这些当前问题。该测定将所有 7 种自身抗体测试组合到一个孔中。每个孔包括三个 IAb（IAA、GADA 和 IA-2A）、甲状腺过氧化物酶 （TPOA） 和甲状腺球蛋白 （ThGA） 自身抗体以检测自身免疫性甲状腺疾病、组织谷氨酰胺转移酶 （TGA） 自身抗体（用于乳糜泻）和自身免疫性多腺综合征 （APS-1） 的干扰素 α 自身抗体 （IFNαA）;所有这些都同时筛查T1D和其他相关的自身免疫性疾病。多重ECL检测基于单个ECL检测平台，而是使用多重板将多种自身抗体检测（最多10个）组合到一个孔中。与单一ECL测定的主要区别在于，在液相中形成的每个抗体-抗原复合物通过多重板上的接头系统被限制在每个孔的特定点上。在本研究中，7-Plex ECL 测定针对标准放射性结合测定 （RBA） 和单次 ECL 测定进行了验证，使用大量新诊断的 T1D 患者和年龄匹配的健康对照，从而具有出色的测定灵敏度和特异性。

Watch this Scientific Journal Video about A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases at JoVE.com

A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases

我们模拟了一个简单的多重ECL检测，将7种自身抗体检测组合在一起。该测定能够同时筛查 T1D 和多种其他自身免疫性疾病，包括乳糜泻、自身免疫性甲状腺疾病和自身免疫性多腺综合征 1。

同时筛查1型糖尿病和多种自身免疫性疾病的高通量电化学发光7重检测

Islet autoantibodies (IAbs) are widely used in type 1 diabetes (T1D) diagnosis and prediction. Four major IAbs to insulin (IAA), glutamate ...

a-high-throughput-electrochemiluminescence-7-plex-assay

Research

JoVE Journal

Medicine

2.4K 次观看.  University of Colorado School of Medicine. 我们模拟了一个简单的多重ECL检测，将7种自身抗体检测组合在一起。该测定能够同时筛查 T1D 和多种其他自身免疫性疾病，包括乳糜泻、自身免疫性甲状腺疾病和自身免疫性多腺综合征 1。

视频: A High-Throughput Electrochemiluminescence 7-Plex Assay Simultaneously Screening for Type 1 Diabetes and Multiple Autoimmune Diseases

Mouse Eye Enucleation for Remote High-throughput Phenotyping

The mouse eye is an important genetic model for the translational study of human ophthalmic disease. Blinding diseases in humans, such as macular degeneration, photoreceptor degeneration, cataract, glaucoma, retinoblastoma, and diabetic retinopathy have been recapitulated in transgenic mice.1-5 Most transgenic and knockout mice have been generated by laboratories to study non-ophthalmic diseases, but genetic conservation between organ systems suggests that many of the same genes may also play a role in ocular development and disease. Hence, these mice represent an important resource for discovering new genotype-phenotype correlations in the eye. Because these mice are scattered across the globe, it is difficult to acquire, maintain, and phenotype them in an efficient, cost-effective manner. Thus, most high-throughput ophthalmic phenotyping screens are restricted to a few locations that require on-site, ophthalmic expertise to examine eyes in live mice. 6-9 An alternative approach developed by our laboratory is a method for remote tissue-acquisition that can be used in large or small-scale surveys of transgenic mouse eyes. Standardized procedures for video-based surgical skill transfer, tissue fixation, and shipping allow any lab to collect whole eyes from mutant animals and send them for molecular and morphological phenotyping. In this video article, we present techniques to enucleate and transfer both unfixed and perfusion fixed mouse eyes for remote phenotyping analyses.

The dissection technique illustrates enucleation of the mouse eye for tissue fixation to perform phenotyping in high-throughput screens.

老鼠的眼睛剜除术的远程高通量的表型

The mouse eye is an important genetic model for the translational study of human ophthalmic disease. Blinding diseases in humans, such as macular ...

科研

医学

High Content Screening in Neurodegenerative Diseases

The functional annotation of genomes, construction of molecular networks and novel drug target identification, are important challenges that need to be addressed as a matter of great urgency1-4. Multiple complementary 'omics' approaches have provided clues as to the genetic risk factors and pathogenic mechanisms underlying numerous neurodegenerative diseases, but most findings still require functional validation5. For example, a recent genome wide association study for Parkinson's Disease (PD), identified many new loci as risk factors for the disease, but the underlying causative variant(s) or pathogenic mechanism is not known6, 7. As each associated region can contain several genes, the functional evaluation of each of the genes on phenotypes associated with the disease, using traditional cell biology techniques would take too long. 
	There is also a need to understand the molecular networks that link genetic mutations to the phenotypes they cause. It is expected that disease phenotypes are the result of multiple interactions that have been disrupted. Reconstruction of these networks using traditional molecular methods would be time consuming. Moreover, network predictions from independent studies of individual components, the reductionism approach, will probably underestimate the network complexity8. This underestimation could, in part, explain the low success rate of drug approval due to undesirable or toxic side effects. Gaining a network perspective of disease related pathways using HT/HC cellular screening approaches, and identifying key nodes within these pathways, could lead to the identification of targets that are more suited for therapeutic intervention.
	High-throughput screening (HTS) is an ideal methodology to address these issues9-12. but traditional methods were one dimensional whole-well cell assays, that used simplistic readouts for complex biological processes. They were unable to simultaneously quantify the many phenotypes observed in neurodegenerative diseases such as axonal transport deficits or alterations in morphology properties13, 14. This approach could not be used to investigate the dynamic nature of cellular processes or pathogenic events that occur in a subset of cells. To quantify such features one has to move to multi-dimensional phenotypes termed high-content screening (HCS)4, 15-17. HCS is the cell-based quantification of several processes simultaneously, which provides a more detailed representation of the cellular response to various perturbations compared to HTS. 
	HCS has many advantages over HTS18, 19, but conducting a high-throughput (HT)-high-content (HC) screen in neuronal models is problematic due to high cost, environmental variation and human error. In order to detect cellular responses on a 'phenomics' scale using HC imaging one has to reduce variation and error, while increasing sensitivity and reproducibility. 
	Herein we describe a method to accurately and reliably conduct shRNA screens using automated cell culturing20 and HC imaging in neuronal cellular models. We describe how we have used this methodology to identify modulators for one particular protein, DJ1, which when mutated causes autosomal recessive parkinsonism21. 
	Combining the versatility of HC imaging with HT methods, it is possible to accurately quantify a plethora of phenotypes. This could subsequently be utilized to advance our understanding of the genome, the pathways involved in disease pathogenesis as well as identify potential therapeutic targets.

We describe a methodology combining automated cell culturing with high-content imaging to visualize and quantify multiple cellular processes and structures, in a high-throughput manner. Such methods can aid in the further functional annotation of genomes as well as identify disease gene networks and potential drug targets.

在神经退行性疾病的高内涵筛选

The functional annotation of genomes, construction of molecular networks and novel drug target identification, are important challenges that need to be ...

Cholesterol Efflux Assay

Cholesterol content of cells must be maintained within the very tight limits, too much or too little cholesterol in a cell results in disruption of cellular membranes, apoptosis and necrosis 1. Cells can source cholesterol from intracellular synthesis and from plasma lipoproteins, both sources are sufficient to fully satisfy cells' requirements for cholesterol. The processes of cholesterol synthesis and uptake are tightly regulated and deficiencies of cholesterol are rare 2. Excessive cholesterol is more common problem 3. With the exception of hepatocytes and to some degree adrenocortical cells, cells are unable to degrade cholesterol. Cells have two options to reduce their cholesterol content: to convert cholesterol into cholesteryl esters, an option with limited capacity as overloading cells with cholesteryl esters is also toxic, and cholesterol efflux, an option with potentially unlimited capacity. Cholesterol efflux is a specific process that is regulated by a number of intracellular transporters, such as ATP binding cassette transporter proteins A1 (ABCA1) and G1 (ABCG1) and scavenger receptor type B1. The natural acceptor of cholesterol in plasma is high density lipoprotein (HDL) and apolipoprotein A-I. 
The cholesterol efflux assay is designed to quantitate the rate of cholesterol efflux from cultured cells. It measures the capacity of cells to maintain cholesterol efflux and/or the capacity of plasma acceptors to accept cholesterol released from cells. The assay consists of the following steps. Step 1: labelling cellular cholesterol by adding labelled cholesterol to serum-containing medium and incubating with cells for 24-48 h. This step may be combined with loading of cells with cholesterol. Step 2: incubation of cells in serum-free medium to equilibrate labelled cholesterol among all intracellular cholesterol pools. This stage may be combined with activation of cellular cholesterol transporters. Step 3: incubation of cells with extracellular acceptor and quantitation of movement of labelled cholesterol from cells to the acceptor. If cholesterol precursors were used to label newly synthesized cholesterol, a fourth step, purification of cholesterol, may be required.
The assay delivers the following information: (i) how a particular treatment (a mutation, a knock-down, an overexpression or a treatment) affects the capacity of cell to efflux cholesterol and (ii) how the capacity of plasma acceptors to accept cholesterol is affected by a disease or a treatment. This method is often used in context of cardiovascular research, metabolic and neurodegenerative disorders, infectious and reproductive diseases.

The cholesterol assay is designed to quantitate the rate of cholesterol efflux from cultured cells and the capacity of plasma acceptors to accept cholesterol released from cells. The assay consists of labelling cells with cholesterol, equilibration of cholesterol among intracellular pools and release of cholesterol to an extracellular acceptor.

胆固醇外流检测

Cholesterol content of cells must be maintained within the very tight limits, too much or too little cholesterol in a cell results in disruption of ...

A Modified Precipitation Method to Isolate Urinary Exosomes

Identification of biomarkers that allow early detection of kidney diseases in urine and plasma has been an area of active interest for several years. Urinary exosome vesicles, 40-100 nm in size, are released into the urine under normal conditions by cells from all nephron segments and may contain protein, mRNA and microRNA representative of their cell type of origin. Under conditions of renal dysfunction or injury, exosomes may contain altered proportions of these components, which may serve as biomarkers for disease. There are currently several methods available for isolation of urinary exosomes, and we have previously conducted an experimental comparison of each of these approaches, including three based on ultracentrifugation, one using a nanomembrane ultrafiltration concentrator, one using a commercial precipitation reagent and one using a modification of the precipitation technique using ExoQuick reagent that we developed in our laboratory. We found the modified precipitation method produced the highest yield of exosome particles, miRNA, and mRNA, making this approach suitable for the isolation of exosomes for subsequent RNA profiling. We conclude that the modified exosome precipitation method offers a quick, scalable, and effective alternative for the isolation of exosomes from urine. In this report, we describe our modified precipitation technique using ExoQuick reagent for isolating exosomes from human urine.

This manuscript describes a protocol for isolating exosomes from human urine using a modified precipitation technique.

一种改进沉淀法来隔离尿外来体

Identification of biomarkers that allow early detection of kidney diseases in urine and plasma has been an area of active interest for several years. ...

An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells

In this work we describe a novel approach that combines ex vivo drug sensitivity assays and digital image analysis to estimate chemosensitivity and heterogeneity of patient-derived multiple myeloma (MM) cells. This approach consists in seeding primary MM cells freshly extracted from bone marrow aspirates into microfluidic chambers implemented in multi-well plates, each consisting of a reconstruction of the bone marrow microenvironment, including extracellular matrix (collagen or basement membrane matrix) and stroma (patient-derived mesenchymal stem cells) or human-derived endothelial cells (HUVECs). The chambers are drugged with different agents and concentrations, and are imaged sequentially for 96 hr through bright field microscopy, in a motorized microscope equipped with a digital camera. Digital image analysis software detects live and dead cells from presence or absence of membrane motion, and generates curves of change in viability as a function of drug concentration and exposure time. We use a computational model to determine the parameters of chemosensitivity of the tumor population to each drug, as well as the number of sub-populations present as a measure of tumor heterogeneity. These patient-tailored models can then be used to simulate therapeutic regimens and estimate clinical response.

We describe a high-throughput drug sensitivity assay for primary multiple myeloma cells. It consists of a reconstruction of the bone marrow microenvironment (including extracellular matrix and stroma) in multi-well plates, and a non-invasive method for longitudinal quantification of cell viability.

一个器官高通量系统原发性多发性骨髓瘤细胞的药物敏感性的表征

In this work we describe a novel approach that combines ex vivo drug sensitivity assays and digital image analysis to estimate chemosensitivity and ...

TRUE Gene Silencing: Screening of a Heptamer-type Small Guide RNA Library for Potential Cancer Therapeutic Agents

TRUE gene silencing (termed after tRNase ZL-utilizing efficacious gene silencing) is one of the RNA-directed gene silencing technologies, which utilizes an artificial small guide RNA (sgRNA) to guide tRNA 3&#8242; processing endoribonuclease, tRNase ZL, to recognize a target RNA. sgRNAs can be taken up by cells without any transfection reagents and can downregulate their target RNA levels and/or induce apoptosis in human cancer cells. We have screened an sgRNA library containing 156 heptamer-type sgRNAs for the effect on viability of human myeloma and leukemia cells, and found that 20 of them can efficiently induce apoptosis in at least one of the cancer cell lines. Here we present a protocol for screening of a heptamer-type sgRNA library for potential therapeutic drugs against blood cancers. The protocol includes how to construct the sgRNA library, how to assess the effect of each sgRNA on cell viability, and how to further evaluate the effective sgRNAs by flow cytometry. Around 2,000 hits would be expected to be obtained by screening the full-scale sgRNA library composed of 16,384 heptamers.

Here we present a protocol for screening of a heptamer-type sgRNA library for potential therapeutic drugs against blood cancers.

TRUE基因沉默:一个七聚物型小导RNA库的筛选潜在的癌症治疗药

TRUE gene silencing (termed after tRNase ZL-utilizing efficacious gene silencing) is one of the RNA-directed gene silencing technologies, which utilizes ...

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Many neurodegenerative diseases are&#160;still lacking effective treatments. Reliable biomarkers for identifying and classifying these diseases will be important in the development of future novel therapies. Often&#160;potential new biomarkers do not make it&#160;into the clinic&#160;due to limitations&#160;in their development and&#160;high costs.&#160;However,&#160;targeted proteomics using Multiple Reaction Monitoring Liquid Chromatography-tandem/Mass Spectrometry (MRM LC-MS/MS), specifically using triple quadrupole mass spectrometers, is one method that can be used to rapidly evaluate and validate biomarkers&#160;for clinical translation into diagnostic laboratories. Traditionally, this platform has been used extensively for measurement of small molecules&#160;in clinical laboratories, but it is the potential to analyze proteins, that makes it an attractive alternative to ELISA (Enzyme-Linked Immunosorbent Assay)-based methods. We describe here how targeted proteomics can be used to measure multiplexed markers of dementia, including the detection and quantitation of the known risk factor apolipoprotein E isoform 4 (ApoE4).
In order to make the assay suitable for translation, it is designed to be rapid, simple, highly specific and cost effective. To achieve this, every step in the development of the assay must be optimized for the individual proteins and tissues they are analyzed in. This method describes a typical workflow including various tips and tricks to developing a targeted proteomics MRM LC-MS/MS for translation.
The method development is optimized using custom synthesized versions of tryptic quantotypic peptides, which calibrate&#160;the MS for detection and then spiked into CSF to determine correct identification of the endogenous peptide in the chromatographic separation prior to analysis in the MS. To achieve absolute quantitation, stable isotope-labeled internal standard versions of the peptides with short amino acid sequence tags and containing a trypsin cleavage site, are included in the assay.

We describe a high-throughput, multiplex, and targeted proteomic cerebrospinal fluid (CSF) assay developed with potential for clinical translation. The test can quantitate potential markers and risk factors for neurodegeneration, such as the apolipoprotein E variants (E2, E3 and E4), and measure their allelic expression.

高通量，复用和有针对性的蛋白质组学分析脑脊液量化神经退行性生物标志物和载脂蛋白E亚型状态

Many neurodegenerative diseases are&#160;still lacking effective treatments. Reliable biomarkers for identifying and classifying these diseases will be ...

Induction of Nephrotic Syndrome in Mice by Retrobulbar Injection of Doxorubicin and Prevention of Volume Retention by Sustained Release Aprotinin

Nephrotic syndrome is the most extreme manifestation of proteinuric kidney disease and characterized by heavy proteinuria, hypoalbuminemia, and edema due to sodium retention and hyperlipidemia. To study the pathophysiology of this syndrome, rodent models have been developed based on the injection of toxic substances such as doxorubicin causing podocyte damage. In mice, only few strains are susceptible to this model. In wildtype 129S1/SvImJ mice, the administration of doxorubicin by rapid intravenous injection to the retrobulbar sinus induces experimental nephrotic syndrome that features all the symptoms of human disease including sodium retention and edema. After the onset of proteinuria, mice exhibit increased urinary serine protease activity that leads to the activation of the epithelial sodium channel (ENaC) and sodium retention. Pharmacological inhibition of urinary serine proteases by the treatment with sustained release aprotinin abrogates ENaC activation and prevents sodium retention. This model is ideal to study the pathophysiology of proteasuria, i.e., the excretion of active serine proteases that cause ENaC activation by the proteolysis of its &#947;-subunit. This can be regarded as the primary mechanism of ENaC activation and sodium retention in proteinuric kidney disease.

Here, we describe the induction of experimental nephrotic syndrome in 129S1/SvImJ mice by rapid retrobulbar injection of doxorubicin. We also treat nephrotic mice with sustained release pellets containing aprotinin to inhibit urinary serine protease activity and prevent sodium retention.

球注射阿霉素对小鼠肾病综合征的诱导作用及缓释抑肽酶预防容积保留率的研究

Nephrotic syndrome is the most extreme manifestation of proteinuric kidney disease and characterized by heavy proteinuria, hypoalbuminemia, and edema due ...

High-throughput Nitrobenzoxadiazole-labeled Cholesterol Efflux Assay

Atherosclerosis leads to cardiovascular disease (CVD). It is still unclear whether cholesterol-HDL (cHDL) concentration plays a causal role in atherosclerosis development. However, an important factor in early stages of atheroma plaque formation is cholesterol efflux capacity to HDL (the ability of HDL particles to accept cholesterol from macrophages) in order to avoid foam cell formation. This is a key step in avoiding the accumulation of cholesterol in the endothelium and a part of reverse cholesterol transport (RCT) to eliminate cholesterol through the liver. Cholesterol efflux capacity to serum or plasma in macrophage cell models is a promising tool that can be used as biomarker for atherosclerosis. Traditionally, [3H]-cholesterol has been used in cholesterol efflux assays. In this study, we aim to develop a safer and faster strategy using fluorescent labelled-cholesterol (NBD-cholesterol) in a cellular assay to trace the cholesterol uptake and efflux process in THP-1-derived macrophages. Finally, we optimize and standardize the NBD-cholesterol efflux method and develop a high-throughput analysis using 96-well plates.

Measurement of in vitro cholesterol efflux capacity to serum or plasma in macrophage cell models is a promising tool as a biomarker for atherosclerosis. In the present study, we optimize and standardize a fluorescent NBD-cholesterol efflux method and develop a high-throughput analysis using 96-well plates.

高通量硝基苯并二氮唑标记的胆固醇积液测定

Atherosclerosis leads to cardiovascular disease (CVD). It is still unclear whether cholesterol-HDL (cHDL) concentration plays a causal role in ...

An Improved and High Throughput Respiratory Syncytial Virus (RSV) Micro-neutralization Assay

Respiratory syncytial virus-specific neutralizing antibodies (RSV NAbs) are an important marker of protection against RSV. A number of different assay formats are currently in use worldwide so there is a need for an accurate and high-throughput method for measuring RSV NAbs. We describe here an imaging-based micro-neutralization assay that has been tested on RSV subgroup A and can also be adapted for RSV subgroup B and different sample types. This method is highly reproducible, with inter-assay variations for the reference antiserum being less than 10%. We believe this assay can be readily established in many laboratories worldwide at relatively low cost. Development of an improved, high-throughput assay that measures RSV NAbs represents a significant step forward for the standardization of this method internationally as well as being critical for the evaluation of novel RSV vaccine candidates in the future.

An Improved and High Throughput Respiratory Syncytial Virus RSV Micro-neutralization Assay

This study describes a high throughput, imaging-based micro-neutralization assay to determine the titer of neutralizing antibodies specific for respiratory syncytial virus (RSV). This assay format has been tested on different sample types.

一种改进的高通量呼吸道合胞病毒 (rsv) 微中和检测方法

Respiratory syncytial virus-specific neutralizing antibodies (RSV NAbs) are an important marker of protection against RSV. A number of different assay ...